AstraZeneca announces that Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union to treat certain patients with advanced or recurrent endometrial cancer.

Imfinzi, combined with chemotherapy, followed by Lynparza and Imfinzi, is approved for patients with effective mismatch repair disease (pMMR), while Imfinzi alone is approved for those with defective mismatch repair disease (dMMR).

These approvals are based on the positive results of a Phase III trial, which showed a significant reduction in the risk of disease progression or death.

These new treatments offer better options for patients, particularly those with few alternatives. Regulatory submissions are also underway in other countries, says the company.

Copyright (c) 2024 CercleFinance.com. All rights reserved.